Skip to content
GTM · People Moves · Marketing

Manny Gaspar Appointed as SVP, Sales and Marketing at Remix Therapeutics

Remix Therapeutics names Manny Gaspar SVP, Sales and Marketing, bringing more than a decade in marketing and senior commercial roles at KalVista Pharmaceuticals and Takeda.

By the Hiro News Desk
· 2 min read · Data by Crustdata
Manny Gaspar, from KalVista Pharmaceuticals to Remix Therapeutics

The Move

New role
SVP, Sales and Marketing
Company
Remix Therapeutics
Previously
SVP, Head of US, KalVista Pharmaceuticals
Announced
October 20, 2026

By the Numbers: Remix Therapeutics

Years in marketing
14
Years at KalVista Pharmaceuticals
3
Employees
50
Funding raised
$211 million

Data: Crustdata, as of October 21, 2026

Remix Therapeutics has appointed Manny Gaspar as SVP, Sales and Marketing, adding a seasoned commercial leader to the clinical-stage biotechnology company. Gaspar arrives with more than two decades of experience, including more than a decade in marketing, and most recently served as SVP at KalVista Pharmaceuticals.

A Track Record In Marketing

Gaspar joins from KalVista Pharmaceuticals, rising over 3 years from Vice President, Sales and Marketing to SVP. According to Crustdata people data, that leadership rests on 14 years in the marketing function, within a career that began in 2001.

Before KalVista Pharmaceuticals, Gaspar spent 4 years at Takeda, first as Head of Sales, Hereditary Angioedema and then as Head of Sales and Accounts, Hematology. An earlier chapter at Shire included the role of Senior Director, Hereditary Angioedema Marketing, Immunology Franchise. The incoming commercial chief also holds an MBA in marketing from Saint Joseph's University.

Why It Matters For Remix Therapeutics

Remix Therapeutics develops novel therapies designed to reprogram RNA processing and address disease drivers at their origin. That work led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology now being evaluated in Phase 1 clinical studies.

Backers including The Column Group, ARCH Venture Partners and Atlas Venture have helped the company raise $211 million, most recently a $60 million round in January 2024. Crustdata company data shows a team of 50, up 2% in six months, with 42 people in Greater Boston and headquarters in Watertown, Massachusetts.

Growth Through Acquisition

Remix Therapeutics announced the acquisition of Passage Bio on June 24, 2026, while its Business Development team has grown 25% over 12 months to 10 people.

What's Next

Gaspar, who is based in the Charleston, South Carolina Metropolitan Area, takes charge of sales and marketing from October 2026. The company is building out its leadership bench at the same time, with 8 listings posted in the United States over the past 3 months, including a VP, Head of Commercial Operations and a Head of Medical Affairs.

Hiro News tracks leadership moves across go-to-market teams every day. People, company and job data in this story comes from Crustdata.

Questions and Answers

Who is the new SVP, Sales and Marketing at Remix Therapeutics?

Manny Gaspar takes on the role at Remix Therapeutics from October 2026, having most recently served as SVP at KalVista Pharmaceuticals.

What is Manny Gaspar's background?

Gaspar brings more than a decade in marketing and rose from Vice President, Sales and Marketing to SVP at KalVista Pharmaceuticals. Earlier, Gaspar spent 4 years at Takeda, including as Head of Sales and Accounts, Hematology, and holds an MBA from Saint Joseph's University.

What does Remix Therapeutics do?

Remix Therapeutics is a clinical-stage biotechnology company developing novel therapies designed to reprogram RNA processing. Its compound REM-422, a first-in-class RNA processing modulator in oncology, is being evaluated in Phase 1 clinical studies.

Data byCrustdata· people and company records, retrieved October 21, 2026. Source: Crustdata.